stockrow
Friday 6 November 2026
Export LAB’s income statement to Excel — free account
Standard BioTools Inc.
LAB Healthcare Medical Devices
Standard BioTools Inc.’s revenue for fiscal 2025 (year ended December 2025) was $85.3 million, down 6.24% from fiscal 2024.
- Revenue
- −0.85%
- EPS
- +138.1%
- Free cash flow
- +73.3%
- Total debt
- +0.33%
Quarter to September 2026, against a year earlier
0.63
0.01
+1.61%
Follow LAB
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
4 | 5 | 5 | 5 |
| (16.72%) | 15.40% | 17.61% | 27.86% | ||
| (12.69%) | 12.83% | 14.34% | 22.65% | ||
ROIC |
(29.07%) | (56.34%) | (93.89%) | (54.18%) | |
Return on Tangible Assets |
(20.51%) | 15.76% | 17.86% | 28.96% | |
Average Days of Receivables |
57.45 | 176.19 | 67.94 | 56.12 | |
Free Cash Flow per Share |
(0.22) | (0.24) | (0.21) | (0.17) | |
Free Cash Flow |
(82.65) | (94.48) | (82.58) | (65.65) | |
Capital Expenditures |
(8.30) | (3.82) | (2.28) | (1.39) | |
| Other line items | |||||
Cash ROIC |
(13.50%) | (9.29%) | (8.12%) | (6.45%) | |
Accounts Receivable Turnover |
6.06 | 2.24 | 5.57 | 6.37 | |
Accounts Payable Turnover |
8.18 | 4.39 | 4.96 | 8.02 | |
Inventory Turnover |
2.10 | 1.43 | 2.03 | 1.88 | |
Average Days of Payables |
46.12 | 67.26 | 83.25 | 31.21 | |
Days of Inventory on Hand |
170.45 | 156.19 | 149.03 | 159.25 | |
Tax Rate |
(0.39) | (0.43) | (0.41) | (0.49) | |
Research and Development Expense of Revenue |
30.45% | 26.28% | 21.77% | 16.75% | |
Selling, General and Administrative Expense of Revenue |
128.75% | 114.36% | 102.75% | 91.41% | |
Share Based Compensation of Revenue |
34.70% | 34.12% | 32.02% | 26.46% | |
Interest Coverage |
(2,979.70) | — | — | — | |
Operating CF/Net income |
0.99 | (1.16) | (0.95) | (0.48) | |
Depreciation/Fixed assets |
0.43 | 0.34 | 0.17 | 0.13 | |
Capex/Depreciation |
(1.00) | (0.66) | (0.88) | (0.83) | |
Revenue per Share |
0.22 | 0.22 | 0.22 | 0.21 | |
Operating CF per Share |
(0.19) | (0.23) | (0.21) | (0.16) | |
Capex per Share |
(0.02) | (0.01) | (0.01) | 0.00 | |
Capex to Sales |
0.10 | 0.04 | 0.03 | 0.02 |
Columns are period end dates · fundamentals updated 5 Nov 2026